An Observational Study of Smoflipid vs Intralipid on the Evolution of Intestinal Failure-Associated Liver Disease in Infants With Intestinal Failure.
An Observational Study of Smoflipid vs Intralipid on the Evolution of Intestinal Failure-Associated Liver Disease in Infants With Intestinal Failure.
复制标题
DOI：
10.1002/jpen.1692
复制
发表时间：
2020-05
期刊：
影响因子：
--
通讯作者：
Wales PW
中科院分区：
文献类型：
--
作者：
Belza C;Wales JC;Courtney-Martin G;de Silva N;Avitzur Y;Wales PW
SMOFlipid具有比传统Intraperoid更多样化的脂质特征，已成为我们肠道康复计划中患者的标准脂质。我们的目的是比较接受SMOFlipid与接受Intralidid的肠衰竭（IF）新生儿的结局。这是一项在2008-2016年期间至少随访12个月的IF婴儿的回顾性队列研究。将患者分为2组：第1组接受SMOFlipid;第2组为接受Intralidid的历史队列。主要结局是使用结合胆红素（CB）水平评价肝功能。统计分析包括Mann-Whitney U和χ2检验，α值< 0.05视为显著。获得了我们机构审查委员会的批准。对37例患者进行了评价（17例= SMOFlipid，20例= Intraperoid）。SMOFlipid患者不太可能达到CB 34（24% vs 55%，P = 0.05），50 μmol/L（11.8% vs 45%; P = 0.028），并且不需要Omegaven（0% vs 30%; P = 0.014）。接受SMOFlipid的患者在开始肠外营养（PN）后3个月的CB水平较低（0 vs 36 μmol/L; P = 0.01）。接受SMOFlipid治疗的患者在3个月（−0.932 vs −2.092; P = 0.028）和6个月（−0.633 vs −1.614; P = 0.018）时的体重z评分有所改善。两组之间PN支持患者或人口统计学无差异。使用SMOFlipid可降低IF患者发生IF相关肝病的可能性。
SMOFlipid has a more diverse lipid profile than traditional Intralipid and has become the standard lipid for patients in our intestinal rehabilitation program. Our objective was to compare outcomes in neonates with intestinal failure (IF) who received SMOFlipid against those receiving Intralipid. This was a retrospective cohort study of infants with IF with a minimum follow-up of 12 months in 2008–2016. Patients were stratified into 2 groups: group 1 received SMOFlipid; group 2 was a historical cohort who received Intralipid. The primary outcome was liver function evaluated using conjugated bilirubin (CB) levels. Statistical analysis included the Mann-Whitney U and χ2 tests, with an α value < 0.05 considered significant. Approval was obtained from our institutional review board. Thirty-seven patients were evaluated (17 = SMOFlipid, 20 = Intralipid). SMOFlipid patients were less likely to reach CB of 34 (24% vs 55%, P = 0.05), 50 μmol/L (11.8% vs 45%; P = 0.028), and did not require Omegaven (0% vs 30%; P = 0.014). CB level at 3 months after initiation of parenteral nutrition (PN) was lower in patients receiving SMOFlipid (0 vs 36 μmol/L; P = 0.01). Weight z-scores were improved for patients receiving SMOFlipid at 3 months (−0.932 vs −2.092; P = 0.028) and 6 months (−0.633 vs −1.614; P = 0.018). There were no differences in PN-supported patients or demographics between the groups. Use of SMOFlipid resulted in decreased development of IF-associated liver disease in patients with IF when assessed using biochemical tests.
登录
查看更多内容
DOI：
10.1177/0148607104028003142
发表时间：
2004-05-01
期刊：
JPEN. Journal of parenteral and enteral nutrition
影响因子：
--
作者：
Antebi, H;Mansoor, O;Alcindor, L G
通讯作者：
Alcindor, L G
影响因子：
3.4
作者：
Buchman, A
通讯作者：
Buchman, A
影响因子：
3.6
作者：
Clandinin, MT;VanAerde, JE;Lien, EL
通讯作者：
Lien, EL
影响因子：
3.4
作者：
Diamond, Ivan R.;Grant, Robert C.;Wales, Paul W.
通讯作者：
Wales, Paul W.
影响因子：
3.4
作者：
Goulet, Olivier;Antebi, Helena;Colomb-Jung, Virginie
通讯作者：
Colomb-Jung, Virginie